Ragweed allergen-specific immunoglobulin E (Ragweed-specific IgE)

Ragweed allergen-specific immunoglobulin E (IgE) is an antibody produced by the immune system in response to exposure to pollen from ragweed plants, primarily Ambrosia artemisiifolia. In sensitized individuals, these IgE molecules bind to high-affinity FcεRI receptors on mast cells and basophils; subsequent exposure to ragweed allergens, such as the major allergen Amb a 1, causes cross-linking of these IgE antibodies and triggers the release of inflammatory mediators like histamine (PMID: 30213461). This physiological response is the underlying cause of seasonal allergic rhinitis (hay fever) and can exacerbate allergic asthma. Therapeutic strategies targeting ragweed-specific IgE include allergen-specific immunotherapy (AIT), which uses controlled exposure to ragweed extracts to induce immunological tolerance and reduce IgE-mediated sensitivity (PMID: 26903178). Furthermore, the biologic agent omalizumab acts by binding to the Fc region of circulating IgE, thereby preventing its interaction with effector cells and reducing the overall allergic inflammatory potential (StatPearls: NBK545184).

Other names

Short ragweed-specific IgEAmbrosia artemisiifolia-specific IgERagweed sIgEAnti-Amb a 1 IgE

Allergen immunotherapy (AIT) induces immune tolerance by promoting the production of allergen-specific IgG4 blocking antibodies and regulatory T cells, which suppress the IgE-mediated allergic response (PMID: 26903178). Omalizumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that selectively binds to human immunoglobulin E (IgE), preventing its binding to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils (FDA Label: Xolair).